Skip to main content
    E

    Esperion Therapeutics Inc (ESPR)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $3.18
    +0.00 (+0.00%)

    Last updated: Jul 13, 2026 at 5:00 PM ET

    Esperion Therapeutics Inc (ESPR) Financials: Revenue, Profit and Cash Flow

    Updated May 8, 2026. Financial statements from company filings, amounts in US dollars.

    Esperion Therapeutics reported revenue of $403.13M for the fiscal year ended Dec 31, 2025, up 21.3% from the year before. That year, net income was -$22.68M with a net margin of -5.6%, operating cash flow was -$13.09M and free cash flow was -$13.09M. The quarter ended Mar 31, 2026 had revenue of $80.10M and net income of -$25.20M.

    Revenue and Margins

    The operating margin was 15.0% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $148.36M, a compound annual rate of 18.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$403.13M+21.3%67.9%15.0%-5.6%
    Dec 2024$332.31M+185.7%79.4%16.4%-15.6%
    Dec 2023$116.33M+54.1%62.8%-133.7%-179.9%
    Dec 2022$75.47M-3.8%100.0%-237.8%-309.6%
    Dec 2021$78.45M-65.5%100.0%-289.0%-343.0%
    Dec 2020$227.55M+53.4%100.0%-53.3%-63.1%
    Dec 2019$148.36MN/A100.0%-62.8%-65.5%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$403.13M$332.31M$116.33M$75.47M$78.45M$227.55M$148.36M$0$0$0
    Cost of revenue$129.22M$68.60M$43.27M$0$0$0$0$0$0$0
    Gross profit$273.91M$263.71M$73.07M$75.47M$78.45M$227.55M$148.36M$0$0$0
    Research and development$47.85M$46.24M$86.11M$118.93M$105.97M$146.94M$175.61M$171.49M$147.60M$57.87M
    Operating income$60.27M$54.40M-$155.56M-$179.50M-$226.73M-$121.40M-$93.10M-$204.59M-$168.98M-$76.15M
    Net income-$22.68M-$51.74M-$209.25M-$233.66M-$269.11M-$143.55M-$97.17M-$201.81M-$166.99M-$74.98M
    EBITDA$66.88M$63.98M-$148.82M-$174.45M-$224.49M-$119.20M-$92.98M-$204.54M-$168.39M-$74.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$80.10M$168.45M$87.31M$82.39M$65.00M$69.11M$51.63M$73.83M$137.74M$32.25M$33.97M$25.79M
    Gross profit$80.10M$39.22M$87.31M$82.39M$65.00M$512.00K$51.63M$73.83M$137.74M-$11.02M$33.97M$25.79M
    Operating income-$6.58M$85.23M-$9.96M$7.09M-$22.10M-$4.42M-$16.03M$2.58M$72.27M-$42.37M-$27.53M-$37.06M
    Net income-$25.20M$61.83M-$31.33M-$12.72M-$40.45M-$21.32M-$29.52M-$61.92M$61.02M-$56.34M-$41.25M-$49.94M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $341.28M exceeded cash and equivalents by $173.43M. Shareholder equity was negative, at -$301.96M, as total liabilities of $767.85M exceeded total assets of $465.89M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$465.89M$343.82M$205.80M$247.94M$381.59M$353.26M$214.45M$143.45M$277.83M$245.21M
    Current assets$462.57M$338.00M$201.06M$246.68M$328.97M$345.90M$211.71M$142.63M$203.92M$213.58M
    Cash and equivalents$167.85M$144.76M$82.25M$124.78M$208.89M$304.96M$166.13M$36.97M$34.47M$38.16M
    Total liabilities$767.85M$732.54M$660.79M$571.72M$578.53M$449.39M$194.50M$64.33M$33.14M$16.61M
    Short-term debt$91.80M$54.58M$0$25.53M$14.08M$2.59M$454.00KN/A$1.04M$1.71M
    Long-term debt$249.48M$237.72M$261.60M$259.90M$258.28M$179.37M$0N/A$0$1.02M
    Shareholder equity-$301.96M-$388.72M-$454.99M-$323.78M-$196.94M-$96.13M$19.95M$79.12M$244.69M$228.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$462.53M$465.89M$364.02M$347.08M$324.03M$343.82M$314.11M$352.32M$373.06M$205.80M$221.31M$234.63M
    Total liabilities$770.46M$767.85M$815.38M$780.59M$750.24M$732.54M$684.32M$696.54M$667.36M$660.79M$631.31M$606.60M
    Cash and equivalents$156.16M$167.85M$92.45M$86.06M$114.63M$144.76M$144.72M$189.30M$226.61M$82.25M$114.83M$138.47M
    Shareholder equity-$307.93M-$301.96M-$451.36M-$433.51M-$426.21M-$388.72M-$370.21M-$344.22M-$294.30M-$454.99M-$410.00M-$371.98M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$13.09M-$23.65M-$135.49M-$174.83M-$263.81M-$85.18M-$70.34M-$148.64M-$131.30M-$47.73M
    Capital expenditures$0$317.00K$0$0$0$869.00K$953.00K$151.00K$19.00K$94.00K
    Free cash flow-$13.09M-$23.97M-$135.49M-$174.83M-$263.81M-$86.05M-$71.29M-$148.79M-$131.32M-$47.82M
    Dividends paid$0$0$0$0$0$302.73MN/AN/A$0$0
    Share repurchases$7.50M$0$0$50.00MN/A$55.00M$0$0N/AN/A
    Investing cash flow$0-$317.00K$42.50M$8.10M-$50.48M$21.36M$64.23M$140.45M-$35.85M$10.12M
    Financing cash flow$36.18M$86.48M$50.46M$32.61M$268.22M$201.72M$136.19M$10.69M$163.46M-$1.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$27.72M$45.24M-$4.29M-$31.42M-$22.63M-$34.95M-$35.33M-$7.21M$53.83M-$37.06M-$19.32M-$24.75M
    Capital expenditures$189.00K$189.00K$0$0$0$0$167.00K$77.00K$73.00K$0$0$0
    Free cash flow-$27.91M$45.05M-$4.29M-$31.42M-$22.63M-$34.95M-$35.49M-$7.28M$53.76M-$37.06M-$19.32M-$24.75M
    Last 12 quarters

    Frequently Asked Questions About ESPR

    What is Esperion Therapeutics' annual revenue?

    Esperion Therapeutics reported revenue of $403.13M for the fiscal year ended Dec 31, 2025.

    How fast is Esperion Therapeutics' revenue growing?

    Revenue was up 21.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 74.8%.

    Is Esperion Therapeutics profitable?

    No. Esperion Therapeutics reported net income of -$22.68M for the fiscal year ended Dec 31, 2025, with a net margin of -5.6%.

    How much free cash flow does ESPR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.09M minus capital expenditures of $0 produced free cash flow of -$13.09M.

    How much debt does Esperion Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $249.48M, short-term debt of $91.80M and cash and equivalents of $167.85M.